Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Core Insights - Rani Therapeutics has initiated a Phase 1 clinical trial for RT-114, an orally administered GLP-1/GLP-2 dual agonist, PG-102, aimed at treating obesity [1][4] - The trial will assess safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics of RT-114 [1] - ProGen Co., Ltd. is developing PG-102, which has shown glucose-lowering effects and early weight-loss signals in preclinical and clinical data [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, utilizing the RaniPill® capsule technology [5] - The RaniPill® capsule is designed to replace subcutaneous injections or intravenous infusions with oral dosing [5] Collaboration Details - RT-114 is developed under a Collaboration Agreement between Rani and ProGen, established in June 2024, sharing development costs and profits equally [6] - Rani will lead the development of RT-114 through Phase 1 trials and will take charge of commercialization in the U.S., Canada, Europe, and Australia after the first Phase 2 trial [6]